Champions Oncology Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 50/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Champions Oncology Inc's Score
Industry at a Glance
Industry Ranking
50 / 404
Overall Ranking
146 / 4582
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
12.000
Target Price
+91.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Champions Oncology Inc Highlights
StrengthsRisks
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.94M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 33.44, at a high 3-year percentile range.
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Ticker SymbolCSBR
CompanyChampions Oncology Inc
CEOBrainin (Robert)
Websitehttps://championsoncology.com
FAQs
What is the current price of Champions Oncology Inc (CSBR)?
The current price of Champions Oncology Inc (CSBR) is 7.220.
What is the symbol of Champions Oncology Inc?
The ticker symbol of Champions Oncology Inc is CSBR.
What is the 52-week high of Champions Oncology Inc?
The 52-week high of Champions Oncology Inc is 11.990.
What is the 52-week low of Champions Oncology Inc?
The 52-week low of Champions Oncology Inc is 5.592.
What is the market capitalization of Champions Oncology Inc?
The market capitalization of Champions Oncology Inc is 99.55M.
What is the net income of Champions Oncology Inc?
The net income of Champions Oncology Inc is 4.70M.
Is Champions Oncology Inc (CSBR) currently rated as Buy, Hold, or Sell?
According to analysts, Champions Oncology Inc (CSBR) has an overall rating of Buy, with a price target of 12.000.
What is the Earnings Per Share (EPS TTM) of Champions Oncology Inc (CSBR)?
The Earnings Per Share (EPS TTM) of Champions Oncology Inc (CSBR) is 0.216.